Modality
Cell Therapy
MOA
ALKi
Target
CDK2
Pathway
Angiogenesis
PTSDPVPAH
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
~Jun 2023
→ ~Sep 2024
Phase 2
Dec 2024
→ Feb 2029
Phase 2Current
NCT03046557
27 pts·PV
2024-12→2029-02·Active
27 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-202.9y awayPh3 Readout· PV
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Active
Catalysts
Ph3 Readout
2029-02-20 · 2.9y away
PV
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03046557 | Phase 2/3 | PV | Active | 27 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| AMG-415 | Amgen | Phase 1 | CDK2 |